Rafferty Asset Management LLC Trims Holdings in Edwards Lifesciences Corporation $EW

Key Points

• Rafferty Asset Management LLC reduced its holdings in Edwards Lifesciences Corporation by 18.4%, now owning 54,611 shares valued at approximately $3.96 million.
• Edwards Lifesciences reported a quarterly EPS of $0.67, exceeding analysts' expectations, with revenue of $1.53 billion for the quarter, reflecting an 11.9% year-over-year growth.
• Analyst ratings for Edwards Lifesciences range from "Strong Buy" to "Sell," with an average price target of $85.90.

Rafferty Asset Management LLC lessened its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 18.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,611 shares of the medical research company's stock after selling 12,276 shares during the quarter. Rafferty Asset Management LLC's holdings in Edwards Lifesciences were worth $3,958,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $27,000. SouthState Corp bought a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $27,000. Global X Japan Co. Ltd. lifted its holdings in shares of Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC lifted its holdings in shares of Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. Mizuho raised their target price on Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, July 25th. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 29th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Finally, Stifel Nicolaus lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Insider Buying and Selling at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,014 shares of company stock worth $1,698,844. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.24 during mid-day trading on Thursday, hitting $80.98. The stock had a trading volume of 2,501,007 shares, compared to its average volume of 3,587,524. The firm has a market cap of $47.55 billion, a P/E ratio of 11.65, a PEG ratio of 3.92 and a beta of 1.07. The business has a fifty day moving average price of $78.71 and a 200-day moving average price of $75.17. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.